Sandy Elbitar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7807570/publications.pdf

Version: 2024-02-01

1478505 1372567 13 201 10 6 citations h-index g-index papers 14 14 14 478 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia. Metabolites, 2022, 12, 262.	2.9	1
2	Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. Metabolites, 2022, 12, 504.	2.9	1
3	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Metabolites, 2021, 11, 564.	2.9	5
4	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports, 2018, 8, 1943.	3.3	25
5	Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1. Journal of Clinical Lipidology, 2018, 12, 1374-1382.	1.5	6
6	High prevalence of ventricular repolarization abnormalities in people carrying TGF \hat{l}^2 R2 mutations. Scientific Reports, 2018, 8, 13019.	3.3	4
7	Plasma proproteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 943-953.	4.4	17
8	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports, 2017, 19, 49.	4.8	31
9	Usefulness of the genetic risk score to identify phenocopies in families with autosomal dominant hypercholesterolemia?. Atherosclerosis, 2017, 263, e83.	0.8	0
10	Plasma PCSK9 and cardiovascular events in type 2 diabetes. Atherosclerosis, 2017, 263, e81.	0.8	1
11	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1377-1392.	5.0	23
12	Identification of a new mutation in the N-terminal region of the apolipoprotein B gene in familial hypercholesterolemia. Atherosclerosis, 2016, 252, e34.	0.8	0
13	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. Current Atherosclerosis Reports, 2014, 16, 439.	4.8	87